Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02706626
Title Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Criterium, Inc.
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST